Compare ASMB & LWLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | LWLG |
|---|---|---|
| Founded | 2005 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.6M | 578.6M |
| IPO Year | 2010 | N/A |
| Metric | ASMB | LWLG |
|---|---|---|
| Price | $36.12 | $4.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $43.40 | N/A |
| AVG Volume (30 Days) | 131.0K | ★ 987.3K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,191,000.00 | $100,605.00 |
| Revenue This Year | $42.01 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.30 | N/A |
| 52 Week Low | $7.75 | $0.79 |
| 52 Week High | $39.71 | $6.26 |
| Indicator | ASMB | LWLG |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 45.41 |
| Support Level | $35.05 | $3.89 |
| Resistance Level | $38.82 | $4.43 |
| Average True Range (ATR) | 1.91 | 0.29 |
| MACD | -0.32 | 0.01 |
| Stochastic Oscillator | 42.70 | 48.21 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.